<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821067</url>
  </required_header>
  <id_info>
    <org_study_id>FS20081121</org_study_id>
    <nct_id>NCT00821067</nct_id>
  </id_info>
  <brief_title>The Effect of Oral D-Ribose in &quot;Baby Boomers&quot; With Fatigue. A Randomized, Double-Blind Study</brief_title>
  <official_title>The Effect of Oral D-Ribose in &quot;Baby Boomers&quot; With Fatigue. A Randomized, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioenergy Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioenergy Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      D-ribose, a natural occurring pentose carbohydrate, has repeatedly shown to enhance&#xD;
      high-energy phosphates and improve function following ischemia, states of congestive heart&#xD;
      failure, and recently in subjects with lung disease. An initial preliminary, open label pilot&#xD;
      study demonstrated a positive benefit of D-ribose in &quot;Baby-Boomer&quot; subjects aged 50 to 65&#xD;
      years old complaining of persistent fatigue. The objective of this study will build on the&#xD;
      previously collected data to evaluate oral D-ribose vs. dextrose (administered as a&#xD;
      supplement) in relatively healthy, yet fatigued subjects with a goal of improving their state&#xD;
      of fatigue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CPX parameters relative to placebo as measured by:</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 at AT</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventilation Efficiency Slope</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen Uptake Efficiency Slope</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate to METS ratio at AT</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Net Energy Expenditure at AT</measure>
    <time_frame>Two weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective will be to subjectively evaluate the subjects' level of fatigue and will be assessed by a serial questionnaire.</measure>
    <time_frame>Two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 6 gm/day (3 gm/bid) dose of D-ribose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A 6 gm/day (3 gm/bid) dose of dextrose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D-ribose</intervention_name>
    <description>A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dextrose</intervention_name>
    <description>A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presents with complaint of fatigue with duration longer than one month&#xD;
&#xD;
          -  Males/Females between the ages of 50 and 65 years of age&#xD;
&#xD;
          -  No previous clinical diagnosis of pulmonary, cardiac or metabolic disorders based on&#xD;
             history&#xD;
&#xD;
          -  Capable of performing a sub-maximal incremental treadmill exercise using&#xD;
             cardiopulmonary analysis methods&#xD;
&#xD;
          -  Normal blood pressure or those with mild, untreated pre-hypertension (&gt;120/70 or &lt;&#xD;
             140/90 mmHg)&#xD;
&#xD;
          -  Able to be compliant with the supplement regimen, repeat clinical visits and&#xD;
             completion of the study questionnaires&#xD;
&#xD;
          -  Must be able to understand the consent form, agree to participate, and to execute&#xD;
             their signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not presently taking any adenine nucleotide enhancing supplements&#xD;
&#xD;
          -  History of non-compliance in previous studies&#xD;
&#xD;
          -  Known to be pregnant&#xD;
&#xD;
          -  Uncontrolled cardiac arrhythmias causing symptoms or unstable hemodynamics&#xD;
&#xD;
          -  Moderate to severe gout&#xD;
&#xD;
          -  A diagnosis of arthritis of the lower extremities&#xD;
&#xD;
          -  Mental impairment, inability to cooperate&#xD;
&#xD;
          -  History of acute non-cardiopulmonary disorder that may affect exercise performance,&#xD;
             (e.g. infection, renal failure, thyrotoxicosis, etc.)&#xD;
&#xD;
          -  Any disorder or condition that in the opinion of the study physician would render&#xD;
             exercise unsafe or would impact exercise performance&#xD;
&#xD;
          -  Any person who is incarcerated, or on a work release program&#xD;
&#xD;
        Additional Exclusions observed and sequelae during initial baseline evaluation:&#xD;
&#xD;
          -  Drop in systolic blood pressure of &gt;10 mm Hg from baseline despite an increase in&#xD;
             workload, when accompanied by other evidence of ischemia&#xD;
&#xD;
          -  Moderately severe angina&#xD;
&#xD;
          -  Increasing nervous system symptoms (e.g. ataxia, dizziness, or near syncope)&#xD;
&#xD;
          -  Signs of poor perfusion (cyanosis or pallor)&#xD;
&#xD;
          -  Technical difficulties monitoring the ECG or systolic blood pressure&#xD;
&#xD;
          -  Subject's desire to stop&#xD;
&#xD;
          -  Sustained ventricular tachycardia&#xD;
&#xD;
          -  Electrocardiographic ST elevation (+1.0 mm) in leads without diagnostic Q-waves (other&#xD;
             than V1 or aVR)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aurora Denver Cardiology Association</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jeff Thompson</name_title>
    <organization>Bioenergy Life Science, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

